BTG Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (45)

Electronic Access - Single User License $600 Buy Now
CD-ROM Mail Delivery $900Buy Now
Hard Copy Mail Delivery $900 Buy Now
Electronic Access - Multi-User License $1200 Buy Now


“BTG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by BTG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline. There are 4 cancer drugs by BTG which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“BTG - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“BTG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by BTG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline. There are 4 cancer drugs by BTG which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“BTG - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. BTG

  1.1 Business Overview

  1.2 BTG Cancer Pipeline Overview

 

2. BTG Cancer Drugs in Preclincal Phase

  2.1 Adenovirus-Based Cancer Therapy – BTG

 

3. BTG Cancer Drugs in Phase-I

  3.1 ONX 0801

 

4. BTG Cancer Drugs in Phase-I/II

  4.1 Ovarian Cancer Vaccine - Life Research Technologies

 

5. BTG Cancer Drugs in Phase-III

  5.1 Uridine Triacetate

 

6. Marketed Cancer Drugs by BTG

  6.1 Irinotecan-Eluting Beads (DEBIRI & PARAGON Bead)

  6.2 Abiraterone Acetate (Zytiga)

  6.3 Raltitrexed (Tomudex)

  6.4 Doxorubicin-Eluting Beads (DC Bead, LifePearl & PRECISION Bead)

 

7. No Development Reperted in Cancer Drugs in Clinical Pipeline

  7.1 Plevitrexed

  7.2 Acadesine

  7.3 Thymidylate Synthase (TS) Inhibitors - BTG PLC

  7.4 Topoisomerase Inhibitors – BTG

  7.5 CI 1010

  7.6 AQ6N

  7.7 RB 6145

 

 8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 Idoxifene

  8.2 Paclitaxel Controlled-Release – BTG

  8.3 Banoxantrone

  8.4 Tretazicar/Caricotamide

  8.5 Hypoxia-Inducible Factor 1 Alpha Inhibitors – BTG

  8.6 C17-20 Lyase Inhibitors - ICR/BTG

  8.7 Tamoxifen Liposomal


Figure 1-1: BTG Cancer Pipeline by Phase (%)

Figure 1-2: BTG Cancer Pipeline by Phase (Number)

Figure 1-3: BTG Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: BTG Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)